Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Nutra Pharma
Drug Discovery
Medical Devices
Investor Relations
Corporate Overview
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Welcome to Nutra Pharma

Drug Discovery and Medical Devices

Nutra Pharma Corp. operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. Additionally, the company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.

Drug Discovery

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Nyloxin® is protected under patent #7,902,152, Use of cobratoxin as an analgesic. In December of 2014, the Company launched Pet Pain-Away - the first OTC product to treat pain in companion animals without side effects.

The Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Nutra Pharma has completed pre-clinical and animal models for their MS and HIV applications and are preparing to move into pivotal Phase II trials. Nutra Pharma's MS drug was recently granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis. .

Learn More
Shareholder Letter

CEO Rik Deitsch has posted a Letter to Shareholders: reviewing 2016 and looking forward to 2017. The letter can be viewed on the following link:Download here

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
December 27, 2016
Nutra Pharma Letter to Shareholders

November 15, 2016
Nutra Pharma Announces Infomercial Campaign for Pet Pain-Away

November 09, 2016
Nutra Pharma Announces Licensing and Marketing Agreement for Pet Pain-Away

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics